Review of Pharmacology - 9E (2015)

General Pharmacology
30
Review of Pharmacology
156. All of the following cross plasma membrane except:
(a) Epinephrine (DNB 2006, 2003)
(b) Thyroxine
(c) Androstenedione
(d) Estrogen
157. G-coupled protein receptor is: (UP 2006)
(a) Metabotropic receptors
(b) Ionic receptors
(c) Kinase-linked receptors
(d) Nuclear receptors
158. About inverse agonism, true is: (MH 2006)
(a) Action on the target receptors is similar to that of
agonist
(b) Binds to the same receptor receptor binding-site as
an agonist for that receptor but exerts the opposite
pharmacological effect
(c) Acts on receptors which do not have agonist
(d) None
159. Antagonism between acetylcholine and atropine:
(a) Competitive antagonism (MH 2006)
(b) Physiological antagonism
(c) Noncompetitive antagonism
(d) None
160. Michaelis Menton constant is: (AP 2004)
(a) Concentration of drug at which the reaction velocity
is half of maximum
(b) Concentration of drug at which the reaction velocity
is maximum
(c) Both
(d) None
161. When two different chemicals act on two different
receptors and their response is opposite to each other
on the same cell, this is called as: (AP 2006)
(a) Physiological antagonism
(b) Chemical antagonism
(c) Reversible antagonism
(d) Competitive antagonism
162. Agonist is having: (Bihar 2006)
(a) Affinity with intrinsic activity is 1
(b) Affinity with intrinsic activity is 0
(c) Affinity with intrinsic activity is-1
(d) None
Therapeutic index and TDM
163. Therapeutic monitoring of plasma level of drug is done
when using all of the following drugs except: (AI 2012)
(a) Warfarin
(b) Gentamicin
(c) Cyclosporine
(d) Phenytoin
164. Therapeutic Drug Monitoring (TDM) involves
measurement of plasma concentrations of drugs to find
whether the drug levels are within the therapeutic range
or not. For TDM to be clinically useful the following
criteria should be fulfilled: (Delhi PG 2011)
(a) There should be good relationship between plasma
concentration and drug dosage
(b) The relationship between plasma drug concen tration
and therapeutic response and/or toxicity should be poor
(c) When pharmacodynamic tolerance is suspected
(d) When the clinical response cannot be easily
monitored
165. Therapeutic index is a measure of: (AI-2008)
(a) Safety
(b) Potency
(c) Efficacy
(d) Selectivity
166. Therapeutic drug monitoring is required in all except:
(a) Phenytoin (AIIMS Nov., 2007)
(b) Metformin
(c) Tacrolimus
(d) Cyclosporin
167. Drugs having narrow theraputic index are:
(a) Lithium (PGI Dec. 2002)
(b) Erythromycin
(c) Phenytoin
(d) Propanolol
(e) Tricyclic antidepressants
168. Therapeutic drug monitoring is required for:
(a) Prodrugs
(b) Levodopa
(c) Lithium carbonate
(d) MAO inhibitors
169. Therapeutic drug monitoring of plasma concentrations
of antihypertensive drugs is not practiced because:
(a) Determination of plasma level of these drugs is quite
tedious and long process
(b) It is easier to measure the effect of these drugs
(c) Antihypertensive effect do not increase linearly with
the dose
(d) All antihypertensive drugs are prodrugs
170. Drug having very narrow therapeutic range is:
(a) Lithium (Karnataka 2009)
(b) Sertraline
(c) Roboxetine
(d) Dothiepin
171. Which of the following drug needs serum level
monitoring? (Karnataka 2009, MPPG 2002)
(a) Lorazepam
(b) Lithium
(c) Amitryptylline
(d) Haloperidol
172. Which one of the following drugs has narrow
therapeutic range? (MPPG 2007 MPPG 2004)
(a) Propanolol
(b) Phenytoin
https://kat.cr/user/Blink99/